FIGURE 7.

LIQ treatment could not protect against LPS-induced cardiomyocyte injuries after inhibiting AMPK activity in vitro (A) CCK-8 kit was used to examine cell viability after treating different concentration of LIQ (0, 1, 10, 20, 40, 80, 160, 320 µM) for 12 h (n = 9), (B) CCK-8 was used to examine cell viability in different treatment as indicated in the picture (n = 9), NRCMs were pretreated with LIQ for 2 h and then were treated with LPS (1 μg/ml) for another 12 h, RT-PCR was performed to analyze mRNA expression of IL-1β (C), IL-6 (D) and TNF-α (E), all of the mRNA expression were normalized to GAPDH before the relative quantitative analysis (n = 6). (F) representative western-blots of phosphorylated AMPKα2 (p-AMPKα2), total-AMPKα2 (T-AMPKα2), p-P65, T-P65, p-IκBα, T-IκBα, BAX, Bcl2, PGC1α, PGC1β and GAPDH (n = 6), relative quantitative analysis proteins expression of p-AMPKα2/T-AMPKα2 (G), p-P65/T-P65 (H), p-IκBα/T-IκBα (I), BAX/GAPDH (J), Bcl2/GAPDH (K), PGC1α/GAPDH (L) and PGC1β/GAPDH (M) (n = 6), all proteins were normalized to GAPDH before the quantitative analysis. The cell experiment was repeated 3 times independently. *p < 0.05 compared with the indicated group, the data were expressed as the Mean ± SEM and were compared by one-way ANOVA with Tukey post hoc analysis.